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Introduction: Few literatures have studied the blood management in patients treated with staged bilateral primary
total knee arthroplasty (TKA) in a single hospitalization period. Therefore, this study aims to evaluate the
effectiveness and safety of the newly introduced multimodal blood management (MBM) in these patients.
Materials and methods: We retrospectively compared the perioperative parameters in 70 cases undergoing
staged bilateral primary TKA in a single hospitalization period from 2012–2013 in a single center with two different
groups of patients, allocating cases to the group with the newly introduced MBM (Group A, n =33) and controls to
the group without the newly introduced MBM (Group B, n =37). The newly introduced MBM protocols include
preoperative hemoglobin (Hb) evaluation, high protein diet, tourniquet release after skin closure, preoperative oral
iron treatment and femoral canal obturation, and one dose of tranexamic acid (TXA) IV with another one if
necessary. While in the control group, only routine blood-saving techniques were used.
Results: Group A had a transfusion rate of 9% (3/33), whereas 32.4% of patients (12/37) in Group B received
allogenic blood transfusion. Significant benefits were also found in Group A in terms of postoperative Hb and
hematocrit (Hct), reduction of postoperative pain, swelling, postoperative pain, length of stays, and hospital costs.
No deep vein thrombosis (DVT) events were found in all these patients.
Conclusions: The newly introduced MBM in staged bilateral TKA in a single hospitalization period can reduce
blood loss effectively as well as pain and knee joint swelling instead of leading to increased complications and
result in significant cost savings.
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Total knee arthroplasty (TKA) is routinely used to treat
end-staged knee diseases. It is well tolerated in the cor-
rectly selected patients, and the results are satisfactory
in a high portion of them. Though the patient’s recovery
is promising, yet significant intraoperative and postopera-
tive blood loss can occur [1,2]. According to a previous
study [3], the blood loss associated with unilateral primary
TKA varies between 1,500 and 2,000 mL, which can reach
up to as much as approximately 40% of the body’s total
blood loss. This situation is worse in the patients treated
with simultaneous bilateral or short-interval bilateral TKA,
despite many benefits, such as reductions both in costs* Correspondence: peifuxing1951@163.com
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unless otherwise stated.and length of hospital stays, better consequences of phys-
ical therapy, and earlier resolution of symptoms [4].
Thus alternative strategies, both pharmacologic and
non-pharmacologic treatments, for reducing blood loss
have been developed. With currently available evidences,
some of the approaches, such as tranexamic acid (TXA)
[5], can minimize the blood loss. Whether others, such
as the use of tourniquet [6], can minimize the blood loss
still remains controversial.
More and more studies report that the multimodal
blood management can reduce perioperative blood loss
associated with TKA effectively [7]. Since 2012, our center
has conducted a newly introduced multimodal blood man-
agement (MBM). By taking this study, we want to address
the following study questions: (1) How much can this
newly introduced MBM minimize the perioperative blood
loss and related parameters, such as transfusion rate. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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TKA during within a single hospitalization period? (2) Are
there any other benefits patients can gain from the newly
introduced MBM? (3) Is it safe to use the newly intro-
duced MBM?
Materials and methods
This retrospective study, based on data collected in our
prospective database and approved by the Institutional
Review Board of our institution, was performed at our cen-
ter from January 2012 to December 2013 (No. 201111009).
All patients, aged 18 years and older, who were scheduled
for bilateral TKA in a single hospitalization period, were
eligible for inclusion in the study. Exclusion criteria in-
cluded revision, flexion deformity ≥30°, varus/valgus de-
formity ≥30°, preoperative hemoglobin (Hb) >120 g/L,
contraindications for the use of TXA, and coagulation dis-
orders. They were informed about the purpose of this
study and given the written informed consent preopera-
tively. Each patient selected the plan that he or she pre-
ferred after the surgeon explained to them the potential
advantage and disadvantage of each plan. All the surgeries
were performed by one surgical team, composed of seven
senior orthopedic surgeons. During this period, 72 adult
patients undergoing primary staged TKA in a single
hospitalization agreed to participate in this study. Two
cases were dropped due to incomplete information. Two
comparative groups were created: Group A, study group in
which we applied the newly introduced MBM; and Group
B, control group in which we applied another approach; 33
patients were allocated to Group A and 37 to Group B.
The routine perioperative blood management used in
both groups includes preoperative Hb evaluation (Hb
level >120 g/L) and preoperative oral iron treatment,
tourniquet with 100 mmHg above systolic pressure,
femoral canal obturation with bone graft, and 12-h con-
tinuous drainage.
In Group A, the surgeons adhered to the newly intro-
duced MBM that includes a perioperative high diet, one
dose of IV-administered TXA (15 mg/kg) before infla-
tion of the tourniquet, and additional one dose of IV-
administered TXA (10 mg/kg) if the drainage volume of
the first 3 h is more than 300 mL.
The surgical team performed TKA in the standard way,
using a midline skin incision, a standard medial parapatel-
lar approach, and a measured resection technique. Three
varieties of cemented total knee systems were used: the
Scorpio NRG (Stryker Allendale, NJ, USA), PFC (Depuy,
IN, USA), and Triathlon (Stryker Allendale, NJ, USA). All
patients were operated under general anesthesia.
A half dose of low-molecular weight heparin (LMWH)
(0.2 mL 2,000 IU) was started 6 h postoperatively and re-
peated at 24-h intervals with a full dose (0.4 mL 4,000 IU)
in the subsequent days if there was no contraindication.Besides, an intermittent foot sole pump system was used
as a routine practice to prevent deep vein thrombosis
(DVT). After the discharge, 10 mg rivaroxaban was ad-
ministered orally to the patients for 10 days if no bleeding
events happened. Doppler ultrasound was used to diag-
nose the deep vein thrombosis on postoperative day 1
(POD1), postoperative day 3 (POD3), the time of discharge,
and 1 month postoperatively.
To ensure the similar cohorts, we calculated the age at
the time of surgery, body mass index (BMI), American
Society of Anesthesiologists (ASA) grade, knee range of
motion (ROM), preoperative visual analog scale (VAS),
and preoperative Hospital for Special Surgery (HSS) knee
scores. The preoperative knee circumferences at both the
upper pole of the patella and the lower pole of the patella
were measured to ensure similar patient body habitus.
Measurements were taken when the patients were placed
in their knee extension position.
We made a comparison in terms of operative time,
tourniquet time, estimated blood loss, the length of hos-
pital stays, drainage volume, transfusion requirements,
and hospital costs between the two groups. As the pri-
mary outcomes of this study, Hb and hematocrits (Hct)
were measured immediately preoperatively, immediately
postoperatively, and on postoperative days 1, 2, and 3.
Estimated blood loss was calculated using the modified
Gross formula. The criterion for a blood transfusion was
set as an Hb level of <70 g/L or 70 g/L ~100 g/L with
symptomatic anemia.
Function was assessed by means of HSS. The HSS
score was got at the time of charge and discharge to find
out the different functional outcomes between groups.
Perioperative VAS pain scores were obtained by a phys-
ician assistant blinded to the type of blood management.
All clinical data were compiled and collected by a separ-
ate research associate.
All data management and statistical analysis were
performed with SPSS version 18.0 software (SPSS Inc.,
Chicago, IL, USA). The Student t test and Fisher exact test
were used to compare data between the two groups. Pa-
rameters that were measured in the same group but at dif-
ferent times were analyzed with the repeated measures




The patient demographics and clinical data were com-
parable between the two groups, as shown in Table 1.
Both Hb and Hct levels in the two groups showed sig-
nificant decreases postoperatively, and they both reached
the lowest point on the postoperative day 3 of each sur-
gery (Figures 1 and 2). The mean levels of Hb and Hct
showed significant advantages in Group A at each time






Age* (year) 62.7 (10.4) 62.0 (12.3) 0.816
Gender (M/F) 4/29 9/28 0.230
BMI* 26.0 (3.7) 26.3 (3.4) 0.668
ASA grade* 2.0 (0.5) 2.0 (0.6) 0.886
Involved diseases
OA 4 6 0.616
RA 29 31
Preoperative Hb* (g/L) 131.2 (5.9) 132.1 (5.6) 0.514
Preoperative Hct* (%) 40.2 (1.5) 40.4 (2.7) 0.701
Preoperative serum level
of albumin* (g/L)
43.0 (3.5) 42.9 (4.6) 0.947
Preoperative VAS pain score* 8.1 (0.9) 8.1 (1.0) 0.821
Preoperative HSS (points)* 38.7 (9.8) 38.2 (6.5) 0.739
Abbreviations: BMI body mass index, OA osteoarthritis, RA rheumatoid arthritis,
Hb hemoglobin, Hct hematocrit, ASA American Society of Anesthesiologists,
VAS visual analog scale, HSS Hospital for Special Surgery.
*The values are given as mean ± standard deviation.
Figure 2 The perioperative levels of hematocrits (Hct) at each
time point. Pre OP preoperative, POH1(F) 1st hour after the first
surgery, POD1(F) 1st day after the first surgery, POD3(F) 3rd day after
the first surgery, POH1(S) 1st hour after the second surgery, POD1(S)
1st day after the second surgery, POD3(S) 3rd day after the second
surgery. The asterisks indicate values that were significantly different
between the groups.
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that is 123.6 ± 7.0 VS 120.3 ± 6.5 (p =0.04); 37.8 ± 1.7%
VS 35.7 ± 1.9% (p <0.001) at 1 h after the first surgery
(POH1(F)), 120.2 ± 7.2 VS 112.5 ± 5.8 (p <0.001); 37.8 ±
1.9% VS 35.7 ± 2.1% (p <0.001) on the 1st day after
the first surgery (POD1(F)), 112.2 ± 6.6 VS 104.3 ± 6.3Figure 1 The perioperative levels of hemoglobin (Hb) at each
time point. Pre OP preoperative, POH1(F) 1st hour after the first
surgery, POD1(F) 1st day after the first surgery, POD3(F) 3rd day after
the first surgery, POH1(S) 1st hour after the second surgery, POD1(S)
1st day after the second surgery, POD3(S) 3rd day after the second
surgery. The asterisks indicate values that were significantly different
between the groups.(p <0.001); 35.6 ± 2.4% VS 32.8 ± 2.5% (p <0.001) on
the 3rd day after the first surgery POD3(F), 107.6 ± 6.8
VS 98.7 ± 6.3 (p <0.001); 34.5 ± 2.7% VS 31.0 ± 2.5%
(p >0.001) at 1 h after the second surgery (POH1(S)),
101.2 ± 7.3 VS 89.8 ± 6.2 (p <0.001); 31.2 ± 2.2% VS
27.7 ± 1.8% (p <0.001) on the 1st day after the second
surgery (POD1(S)), 93.6 ± 5.6 VS 85.2 ± 4.0 (p <0.001);
28.7 ± 1.7% VS 25.1 ± 1.8% (p <0.001) on the 3rd day
after the second surgery (POD3(S)) (Figures 1 and 2).
Significant differences were observed between the
groups in terms of drainage volume and estimated blood
loss (Table 2). A mean decrease of 603 mL of estimated
blood loss was found in Group A (p <0.001). As to the
hidden blood loss and the highest changes of both Hb and
Hct, priority was also revealed in Group A (Table 2).
When transfusions were compared for surgeries per-
formed with different blood managements, significantly
different transfusions rates were found: mean in Group A
was 9% (n =3/33), and in Group B was 32.4% (n =12/37)
(p =0.021) (Table 2). As to the number of transfusions per
patient, less transfusion was also observed in the patients
of Group A (0.24 ± 0.83 IU VS 0.81 ± 1.28 IU, p =0.030)
(Table 2).
Nutritional status
The extent of the serum levels of albumin at different
time points was listed as primary outcomes which can
reflect the nutritional status of the patients. Significant
differences were detected between the two groups on






Duration of surgery* (min) 117.7 (17.1) 121.5 (15.7) 0.336
Drainage volume* (mL) 279.2 (78.0) 458.4 (96.4) <0.001‡
Calculated blood loss* (mL) 1227.2 (196.1) 1830.2 (349.6) <0.001‡
Hidden blood loss* (mL) 947.9 (200.9) 1371.9 (372.7) <0.001‡
Interval days* (d) 3.4 (0.6) 3.6 (0.5) 0.345
Length of stays* (d) 12.4 (1.2) 13.2 (1.5) 0.012‡
The highest changes
of Hb* (g/L)
37.7 (3.8) 47.2 (4.3) <0.001‡
The highest changes
of Hct* (%)
11.6 (1.4) 15.2 (1.6) <0.001‡
HSS score at discharge* (points) 82.1 (5.7) 80.8 (6.8) 0.319
Abbreviations: Hb hemoglobin, Hct hematocrit, HSS Hospital for Special Surgery.
*The values are given as mean ± standard deviation.
‡Significantly different.
Figure 4 The postoperative visual analog scale (VAS) scores at
each time point. POD1(F) 1st day after the first surgery, POD3(F) 3rd
day after the first surgery, POD1(S) 1st day after the second surgery,
POD3(S) 3rd day after the second surgery. The asterisks indicate
values that were significantly different between the groups.
Ma et al. Journal of Orthopaedic Surgery and Research 2014, 9:116 Page 4 of 7
http://www.josr-online.com/content/9/1/116POD3(F) (36.1 ± 3.8 VS 33.5 ± 3.0, p =0.003), POD1(S)
(34.1 ± 3.7 VS 30.8 ± 2.3, p <0.001) and POD2(S) (32.3 ±
2.9 VS 28.5 ± 2.0, p <0.001) (Figure 3).
Pain, swelling, postoperative course, and hospital
cost assessment
Postoperative pain decreased daily though there was a
fluctuation between the POD3(F) and POD1(S). Group
A had slightly less postoperative pain on POD1(F) (4.7 ±
1.1 VS 5.6 ± 1.3, p =0.001) and POD1(S) (4.4 ± 0.6 VS
5.1 ± 1.1, p =0.002) (Figure 4). The results of mean pre-
operative increment of both thigh girth and calf girthFigure 3 The perioperative serum levels of albumin at each
time point. Pre OP preoperative, POD1(F) 1st day after the first
surgery, POD3(F) 3rd day after the first surgery, POD1(S) 1st day after
the second surgery, POD3(S) 3rd day after the second surgery. The
asterisks indicate values that were significantly different between
the groups.showed less severity of swelling on POD1 and POD3
(Table 3). The average length of hospital stay was 12.4 ±
1.2 days in Group A and 13.2 ± 1.5 days in Group B
(p =0.012), while no significant differences were de-
tected in terms of interval days (Table 2). The assess-
ment of hospital costs showed there was an average
increase of ¥1,638 per case in Group B.
Functional assessment
The HSS score was used to assess patients’ knee func-
tion. Baseline demographics were similar between theTable 3 Mean (SD) increments in circumferences of the
leg over time for the two groups
Groups Pre-operation (cm) Preoperative increment†
POD1 POD3
Thigh girtha
Group A 36.5 (3.8) 1.4 (2) 1.2 (1.8)
Group B 37.5 (3.1) 1.5 (1) 1.3 (0.8)
p value 0.246 0.011* 0.001*
Calf girthb
Group A 29.9 (2.0) 0.7 (2) 0.5 (1.6)
Group B 30.3 (2.7) 0.9 (2) 0.6 (1.9)
p value 0.527 0.038* 0.010*
aThigh girth: circumference at the thigh, 10 cm proximal portion form the top
of the patella.
bCalf girth: the maximum circumference of the calf.
†Preoperative increment: increment of the circumference compared with that
of the pre-operation.
*Statistically significant difference between the two groups: p <0.05.
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stantial improvement was found in both groups: mean
HSS scores increased to 82.1 (5.7) in Group A and to
80.8 (6.8) in Group B. Yet, there was no difference ap-
proaching significance between groups in the HSS scores
at discharge, though Group A showed a little bit higher
(Table 2).
Complications
No DVT was found in any patients of the two groups,
while intermuscular venous thrombosis was found in 5
patients of Group A and 3 patients of Group B.
Discussion
With the increasing success of the TKA as an extremely
effective intervention for end-staged knee diseases, how to
improve the effectiveness and lower down the risks of
complications has become the first concern of all the joint
surgeons [1]. Among them, blood loss conservation is a
major one. In this retrospective study, we have compared
the outcomes of the newly introduced MBM with those of
traditional one applied in the patients undergoing staged
bilateral TKA in a single hospitalization period.
Due to its retrospective nature, this study has several
limitations, including the non-randomized design, not
allowing for complete control of the perioperative vari-
ables such as demographics and co-morbidities. In
addition, the use of the different prostheses may contrib-
ute to some limitations. Despite these limitations, the
strengths of our study were as follows: First, this study
focused on a relatively large number of cases; second,
the variables were reduced to a minimum because the
patients were treated by the same surgical team, using
the same familiar surgical technique. In addition, we
were able to pinpoint the exact transfusion needs in
TKA while the current literature on blood management
in orthopedics tends to report contradictory statements
with no definitive conclusions.
One of the important findings in this study is that
the newly introduced MBM can effectively diminish the
reduction of both Hb and Hct levels by 3 days post-
operation. Less calculated blood loss and drainage vol-
ume were also found in Group A. As was reported
previously [1], the lowest Hb and Hct levels always ap-
pear on the postoperative day 3, we believe by taking the
newly introduced MBM, the perioperative blood loss in
the patients undergoing staged bilateral TKA in a single
hospitalization can be effectively reduced. A transfusion
rate of 9% was obtained in Group A, while in Group B the
transfusion rate was 32.4%. We believe that these findings
provide a further proof about the non-pharmacological
protocols—including a high protein diet, many surgical
gestures, not only pharmacological protocols—hematinics,
and TXA.As an inhibitor of fibrinolysis, TXA has gained signifi-
cant popularity in TKA. Many prospective randomized
clinical trials and meta-analysis have reported that TXA
can limit blood loss following unilateral TKA [8,9].
While the literatures in this field are abundant, the lack
of studies related to bilateral TKA makes our study sali-
ent. Recently, Kelley et al. [10] has conducted a retro-
spective case–control study comparing blood loss after
bilateral TKAs staged 3 days apart (2 doses of 1 g) ver-
sus placebo. Significantly less blood loss occurred in the
TXA treatment group versus controls. Also fewer trans-
fusions per patient and total drain output were found in
the TXA group. These finds were quite similar to ours.
However, our TXA administration regimen differed
from the protocols used in that study [10], as we admin-
istered TXA in a single intravenous dose of 15 mg/kg
just before the inflation of the tourniquet. When we
used tourniquet during the surgery, the blood loss of the
surgical field was too little to be calculated, so we con-
sidered it unnecessary to use the TXA before the inci-
sion. Application of pneumatic tourniquet enhances
fibrinolysis as a result of plasminogen activator release
from the vascular endothelium, triggered by hypoxia or
venous stasis. Starting an antifibrinolytic therapy before
tourniquet could interfere with the natural defense
mechanisms of the body against thrombus formation. As
to the dose of TXA, it is still under debate [11-13]. Ac-
cording to a meta-analysis conducted by Cid et al. [11],
the reduction in the risk of receiving a blood transfusion
was independent of the total dose of TXA given. And
some other studies [12] reported the low dose of TXA
(15–35 mg/kg) was sufficient to lower down the blood
transfusion requirement. Since the risk of thrombosis
might increase with the growth of the dose of TXA, we
used the dose of 15 mg/kg.
It was interesting to notice that the hidden blood loss in
Group A was much less than that in Group B, which
seems to be inconsistent with the previous study [14],
which reported that the IV administration of TXA could
only decrease external blood loss instead of the hidden
blood loss after TKA. We contributed the phenomenon to
the reasons as follows: First, the previous study focused on
the unilateral TKA rather than the bilateral ones [14]. So,
the reduction of the hidden blood loss might be too little
to be detected. Second, as a result of using a high protein
diet to the patients in Group A, the reduction of albumin
was slowed down; this might accelerate the repair process
of the tissue and result in the less hidden blood loss. What
is more, a multimodal blood saving protocol was used in
this study, other approaches, such as a high protein diet,
surgical gestures, and hematinics might also have some
impact on it [7,15].
With the decrease of the hidden blood loss in the
joint, the benefit in reducing the joint swelling emerged
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loss and transfusion requirements could be regarded as
a sign of tissue trauma. With less blood loss, the inflam-
mation of the tissue was less severe. Thus, smaller incre-
ment of both thigh girth and calf girth was found on
POD1 and POD3. Additionally, the less severity of the
inflammation of the tissue means less pain, which was
observed on POD1(F) and POD1(S). However, this kind
of advantage disappeared on the POD3(F) and PDO3(S).
We believed the standard postoperative pain control
protocol might contribute to the phenomenon.
As for the length of hospital stays, we found a shorter
length of stay was associated with the application of the
newly introduced MBM. The possible reason why the
length of stays is shorter in Group A is that the patients
could be more aggressively mobilized. It is unnecessary
for the patients to avoid physical therapy to receive
transfusions. Instead it was better for them to participate
in physical therapy, as they did not have symptoms of
anemia. Thus, the patients in Group A could be dis-
charged earlier.
Previously, Sepah et al. [18] and Ralley et al. [13] con-
ducted several studies to assess the costs of using IV-
administered TXA in TKA. In our study, we directly
compared the costs related to the pharmacy, transfu-
sions, and length of hospital stays to calculate the total
direct costs. Although using the newly induced MBM
could cause the rise of the pharmacy costs, this was
more than an offset by the pharmacy costs associated
with a shorter length of hospital stays. The saving was a
total of ¥1,638 per case, which is quite a large sum of
money for a Chinese family.
The theoretical risk of using TXA is thrombosis. A re-
cent meta-analysis by Yang et al. [9] showed the use of
TXA was not associated with increased perioperative
complications. However, Yeager et al. [4] reported the pa-
tients who underwent bilateral TKA were at a higher risk
of developing DVT or even PE. However, we did not see a
significant increase in DVT in our study. The reasons
might be as follows: First, in order to lower down the risk
of DVT, we moved the usage of the LMWH 2 h ahead to
the postoperative 6 h; second, a regular protocol of throm-
bosis prevention, including medical and physical ap-
proaches, was followed well in the patients of both groups
even after the discharge; furthermore, early rehabilitation
activities which can reduce the risk of thromboembolism
were encouraged in the physical therapy process of our
center. What is more, according to the study of Lee [19],
Asians are less likely to develop DVT than Caucasians.
In conclusion, we found that the newly introduced
MBM in staged bilateral TKA in a single hospitalization
can reduce blood loss effectively as well as pain and knee
joint swelling instead of leading to increased complica-
tions and result in significant cost savings.Abbreviations
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